

Aklief (Trifarotene) is a prescription retinoid cream for acne. Learn what it treats, how to use it, who should avoid it, and how much it costs in 2026.
Aklief is a prescription topical retinoid cream used to treat acne vulgaris in patients 9 years of age and older.
Its active ingredient is Trifarotene, a fourth-generation retinoid and the first new retinoid molecule approved for acne treatment in over 20 years. Aklief is manufactured by Galderma Laboratories and comes as a 0.005% cream in a 45g airless pump.
What makes Aklief different from older retinoids like Tretinoin (Retin-A) or Adapalene (Differin)? It's the first retinoid that selectively targets retinoic acid receptor gamma (RAR-γ) — the most common retinoid receptor found in human skin. This selective binding was designed to effectively treat acne while potentially reducing the irritation that comes with less targeted retinoids.
Aklief was FDA-approved in October 2019 and is not available as a generic. Galderma holds patents that extend through approximately 2031 to 2033.
Aklief is FDA-approved for the topical treatment of acne vulgaris in patients 9 years of age and older. This includes acne on the face as well as the trunk (chest, shoulders, and back).
In fact, Aklief is notable for being studied and approved for truncal acne — acne on the body, not just the face. This makes it particularly useful for patients who deal with acne on their chest, shoulders, or back, which many other topical retinoids weren't specifically tested for.
While not FDA-approved for these uses, some dermatologists may prescribe Aklief for:
Aklief is applied once daily in the evening. Here's the step-by-step:
Aklief is not appropriate for everyone. Do not use Aklief if you have:
If you're wondering how Aklief stacks up against other acne retinoids, here's a quick comparison:
For a detailed comparison, read our article on alternatives to Aklief.
Aklief is one of the more expensive topical acne treatments on the market:
There is no generic version of Aklief available, and Galderma's patents extend through approximately 2031 to 2033.
Most insurance plans and Medicare do not cover Aklief, or require prior authorization and step therapy (trying cheaper retinoids like Tretinoin or Adapalene first). If your insurance does cover it, your copay will depend on your plan's formulary tier.
The Galderma CareConnect Patient Savings Card is the best way to reduce your cost. Enroll at galdermacc.com/patients or call 855-280-0543. It's valid for up to 15 uses per calendar year but not available for patients with government insurance (Medicare, Medicaid, Tricare).
For a complete guide to savings options, read how to save money on Aklief.
Aklief (Trifarotene) is a modern, targeted acne treatment that offers real advantages — especially for patients with truncal acne or those who haven't responded well to older retinoids. It's the first new retinoid molecule for acne in over two decades, and its selective RAR-γ mechanism represents a genuine advancement in topical acne therapy.
The main barriers are cost and availability. At $760 or more without savings, it's a significant investment. But with the Galderma savings card, most patients can get it for $20 to $90. Use Medfinder to find a pharmacy that stocks it near you, and read our guides on side effects and how Aklief works to get the most from your treatment.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.